Jove
Visualize
お問い合わせ

関連する概念動画

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

5.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Positive Regulator Molecules02:39

Positive Regulator Molecules

5.7K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー
  1. ホーム
  3. サイクリンd/cdk4軸をターゲットに,がん治療の改善のための新たな治療アプローチを展開する
  1. ホーム
  3. サイクリンd/cdk4軸をターゲットに,がん治療の改善のための新たな治療アプローチを展開する

関連する実験動画

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K

サイクリンD/CDK4軸をターゲットに,がん治療の改善のための新たな治療アプローチを展開する

Ibrahim Khater1, Aaya Nassar1

  • 1Biophysics Department, Faculty of Science, Cairo University, Giza, Egypt.

PloS one
|August 22, 2025

PubMed で要約を見る

まとめ
この要約は機械生成です。

研究者らは,がんと戦うためにサイクリンD/CDK4複合体を標的とする新薬候補を特定した. この研究は,現在のCDK4/ 6阻害剤に対する耐性を克服するための新しい治療戦略を提供します.

さらに関連する動画

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.1K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.4K

関連する実験動画

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.1K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.4K

科学分野:

  • 腫瘍学
  • 分子生物学
  • 薬物の発見

背景:

  • サイクリンD/CDK複合体の調節不良は,大腸癌,乳癌,メラノーマなどの癌の制御不能な細胞サイクル進行を誘導する.
  • 現在,FDAが承認したCDK4/ 6阻害剤 (リボシクリブ,パルボシクリブ,アベマシクリブ) は,臨床的有効性を示しているが,治療抵抗性による課題に直面している.
  • 腫瘍学における耐性を克服し,患者の治療結果を改善するために,新しい治療戦略が不可欠です.

研究 の 目的:

  • サイクリンD/CDK4複合体を標的とする新しい小分子阻害剤を特定する.
  • サイクリンD/CDK不調によって引き起こされるがんに対する代替治療戦略を探求する.
  • 既存のCDK4/ 6阻害剤に関連する耐性メカニズムを回避する新しい治療法を開発する.

主な方法:

  • ZincとPubChemのデータベースの仮想スクリーニングは,PocketQueryによって生成されたファーマコフォアモデルを使用しています.
  • サイクリンD/CDK4複合体の潜在的な新薬阻害剤の特定
  • 抑制剤と標的の相互作用を分析するための分子動力学シミュレーション.

主要な成果:

  • サイクリンD/CDK4複合体を標的とする有望な鉛化合物は,仮想スクリーニングによって特定されました.
  • 特定された候補薬は,次世代のがん治療薬の開発の潜在的な出発点を表しています.
  • この研究は,新しい阻害剤のさらなる最適化と開発のための基礎を提供します.

    • 結論:

    • 特定された化合物は より効果的ながん治療の開発の可能性を示しています.
    • これらの新しい阻害剤は,現在のCDK4/ 6療法に対する耐性を克服するのに役立ちます.
    • 臨床的有効性を確認するために,さらなる実験的検証と in vivo 研究が必要である.